Hadasit Newsletter / February 2018

INNOVATION SPOTLIGHT

Message from the CEO, Dr. Tamar Raz

It is my pleasure to report that 2017 has been a year of growth and advancement as we guide medical technologies from innovation to commercial application. By bringing together science, medicine, academia and business, we are positively impacting the healthcare industry.

In nearly every area- from IP and licensing activities to patent applications and sponsored research- Hadasit has shown significant growth. This is reflected in our total revenues which increased 8% in 2017, the number of R&D service and consulting agreements which increased 35%, license and commercialization activities of Hadassah IP which increased 33%, and patent applications which increased 15% in 2017.

Our goal for 2018 is continued growth and development, bringing even more lucrative deals and commercial partners to Hadassah.■



New Agreements for Human Embryonic Stem Cells Developed at Hadassah

New agreements reaffirm the standing of Hadassah scientist **Prof. Benjamin Reubinoff** as an international leader in the clinical utilization of human embryonic stem cells (hESC). Coming on the heels of previous agreements with Israeli companies such as Cell Cure and Kadimastem, these new agreements with US-based companies mark an important milestone in the global dissemination of Hadassah innovation.

These two new agreements, for the supply of clinical grade hESC developed at Hadassah by **Prof. Benjamin Reubinoff**, were signed with leading US-based start-up companies. Using **Prof. Reubinoff**'s stem-cells, the companies will generate billions of functional cells in the laboratory, leading eventually to the development of cell-based therapies.■

Hadasit Newsletter / February 2018

INNOVATION SPOTLIGHT (p.2)

New Research Collaboration Agreement with Genentech

Hadasit has signed a research collaboration agreement with Genentech, a member of the Roche Group, with over 15,000 employees working to address unmet medical needs across the United States.

Hadassah's researcher is **Prof. Itay Chowers**, Chairman of the Division of Ophthalmology at Hadassah. The collaboration is based on datasets collected by **Prof. Chowers**' research team. The study is aimed to conduct a biomarker algorithm predictive abilities validation.

Ministry of Health Grants Hadassah/Hadasit a GMP Compliance Status

Regulatory approved production capabilities are a critical component in medical translational machinery. So far, we have produced over 50 products for human clinical studies in the Hadassah/Hadasit GMP approved facility. In December 2017, Israel's Ministry of Health granted Hadassah's Good Manufacturing Practice (GMP) biological production facility certification for standing as a GMP-compliant facility. This includes the possibility to produce biologicals for phase III studies.

Hadassah's world-class GMP laboratory, established by **Prof. Eitan Galun**, is where biological and cell based clinical trial materials can be produced by companies and by Hadassah researchers to use in their clinical trials. It is unique and the only such facility in Israel in a biomedical clinical institution.

The proximity of the GMP to the only university-hospital in Israel makes the translational activity most attractive. **Dr. Linda Rasooly** (lindaR@hadassah.org.il) is the management director of the facility and would be happy to answer any questions.

New Face at Hadasit

Dr. Ophra Rickover joined Hadasit in 2017 as our Intellectual Property Director. A certified Israeli patent attorney, she manages Hadassah's IP portfolio and evaluates inventions developed by Hadassah's employees.

Before joining Hadasit, **Dr. Rickover** worked at Omrix Biopharmaceuticals, Ltd., a Johnson & Johnson Company, where she oversaw biological and medical device IP. **Dr. Rickover** holds a Ph.D. in life sciences, an M.A. in biotechnology, and an M.A. in legal studies, all from Bar-Ilan University.